Levetiracetam Aguettant (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action stabilizes neuronal membranes and reduces abnormal neuronal firing, helping to prevent the initiation and spread of epileptic seizures.

The appropriate dose of Levetiracetam Aguettant is determined by the prescribing clinician based on the patient’s age, weight, renal function, seizure type, and clinical response. No fixed dosing regimen is provided here; the prescriber tailors therapy to individual needs.

Safety data for levetiracetam during pregnancy and lactation are limited. Clinicians must weigh potential benefits against possible risks, and the decision should be made on a case‑by‑case basis in consultation with the patient and obstetric specialist.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Levetiracetam has a unique mechanism targeting SV2A, offering broad-spectrum seizure control with a relatively low potential for drug‑enzyme interactions compared with many older antiepileptics. It is often preferred when rapid IV administration is needed or when patients have experienced adverse effects from enzyme‑inducing agents.

Levetiracetam Aguettant should be stored at ambient temperature, protected from light and moisture, and kept in its original packaging. Do not freeze the solution. Before administration, inspect the vial for particulate matter and ensure the solution is clear.

The product is supplied as an intravenous solution and is administered by slow infusion into a vein, typically under the supervision of a healthcare professional. The infusion rate and total daily dose are set by the treating physician according to the patient’s clinical condition.

Serious risks include severe allergic reactions such as anaphylaxis, life‑threatening skin conditions like Stevens‑Johnson syndrome, blood dyscrasias (e.g., neutropenia), and emergence of suicidal thoughts or behavior. Prompt medical evaluation is required if any of these events occur.

Patients with known hypersensitivity to levetiracetam or any component of the formulation should avoid its use. Caution is also advised for individuals with severe renal impairment, uncontrolled psychiatric conditions, or those who are pregnant without a clear risk‑benefit justification.